company background image
A293780 logo

AptaBio Therapeutics KOSDAQ:A293780 Stock Report

Last Price

₩8.18k

Market Cap

₩202.3b

7D

7.3%

1Y

-8.8%

Updated

11 Oct, 2024

Data

Company Financials

AptaBio Therapeutics Inc.

KOSDAQ:A293780 Stock Report

Market Cap: ₩202.3b

A293780 Stock Overview

AptaBio Therapeutics Inc. discovers and develops selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs.

A293780 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

AptaBio Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AptaBio Therapeutics
Historical stock prices
Current Share Price₩8,180.00
52 Week High₩15,490.00
52 Week Low₩4,930.00
Beta1.99
11 Month Change-0.49%
3 Month Change-43.12%
1 Year Change-8.81%
33 Year Change-80.00%
5 Year Change-5.43%
Change since IPO-57.94%

Recent News & Updates

Is AptaBio Therapeutics (KOSDAQ:293780) Using Too Much Debt?

Jul 12
Is AptaBio Therapeutics (KOSDAQ:293780) Using Too Much Debt?

Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money

Mar 26
Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money

Recent updates

Is AptaBio Therapeutics (KOSDAQ:293780) Using Too Much Debt?

Jul 12
Is AptaBio Therapeutics (KOSDAQ:293780) Using Too Much Debt?

Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money

Mar 26
Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money

Do Institutions Own AptaBio Therapeutics Inc. (KOSDAQ:293780) Shares?

Feb 23
Do Institutions Own AptaBio Therapeutics Inc. (KOSDAQ:293780) Shares?

Companies Like AptaBio Therapeutics (KOSDAQ:293780) Can Afford To Invest In Growth

Jan 01
Companies Like AptaBio Therapeutics (KOSDAQ:293780) Can Afford To Invest In Growth

Shareholder Returns

A293780KR BiotechsKR Market
7D7.3%4.3%1.4%
1Y-8.8%43.9%2.8%

Return vs Industry: A293780 underperformed the KR Biotechs industry which returned 43.9% over the past year.

Return vs Market: A293780 underperformed the KR Market which returned 2.8% over the past year.

Price Volatility

Is A293780's price volatile compared to industry and market?
A293780 volatility
A293780 Average Weekly Movement11.8%
Biotechs Industry Average Movement9.1%
Market Average Movement6.8%
10% most volatile stocks in KR Market12.1%
10% least volatile stocks in KR Market3.5%

Stable Share Price: A293780's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A293780's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
2009n/aJin Soowww.aptabio.com

AptaBio Therapeutics Inc. discovers and develops selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX Reagent for transfecting DNA or RNA into eukaryotic cells. Its product candidates include PX-115 for treating diabetic nephropathy; APX-1004 to treat diabetic retinopathy; and APX-311 for use in treating non-alcoholic steatohepatitis (NASH).

AptaBio Therapeutics Inc. Fundamentals Summary

How do AptaBio Therapeutics's earnings and revenue compare to its market cap?
A293780 fundamental statistics
Market cap₩202.29b
Earnings (TTM)-₩15.27b
Revenue (TTM)₩2.06b

98.4x

P/S Ratio

-13.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A293780 income statement (TTM)
Revenue₩2.06b
Cost of Revenue₩1.90b
Gross Profit₩156.29m
Other Expenses₩15.42b
Earnings-₩15.27b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-617.35
Gross Margin7.60%
Net Profit Margin-742.87%
Debt/Equity Ratio30.5%

How did A293780 perform over the long term?

See historical performance and comparison